Craig-Hallum raises Myriad Genetics stock target to USD 8
Published on 10/20/2026 at 20:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and operating figures
- Craig-Hallum raised its target from USD 4.00 to USD 8.00 on October 8, 2026.
- Second-quarter revenue fell 11.00 percent year over year to USD 190.70 million.
- Myriad Genetics stock stood at EUR 5.07 at Lang & Schwarz on October 20, 2026 at 8:35 p.m. CEST.
Craig-Hallum raised its Myriad Genetics target from USD 4.00 to USD 8.00 on October 8, 2026, according to Business Insider. Myriad Genetics stock stood at EUR 5.07 at Lang & Schwarz on October 20, 2026 at 8:35 p.m. CEST.
Revenue remains the key test
Myriad Genetics reported USD 190.70 million of revenue for the second quarter of 2026, down 11.00 percent from the same period a year earlier. The company also lowered full-year 2026 revenue guidance to USD 770 million to USD 790 million, according to the second-quarter earnings call transcript published by Yahoo Finance. The midpoint of the revised range is USD 90 million below the earlier outlook.
What does the target imply?
Craig-Hallum's new USD 8.00 target is double its previous USD 4.00 level. The analyst action gives investors a clearly defined valuation marker, but the revenue decline and reduced guidance show why the next operating update matters more than the target alone.
Oncology collaboration adds a second angle
On October 8, 2026, Myriad Genetics and SOPHiA GENETICS announced a collaboration to advance a prostate cancer genomic instability score for precision oncology. The companies said the technology is intended to support clinical trials and potential companion diagnostic solutions, as reported in the GlobeNewswire. The program uses Myriad's MyChoice CDx platform, which is already available as a companion diagnostic in ovarian cancer.
Myriad Genetics is scheduled to release third-quarter 2026 financial results on November 4, 2026, according to the company's investor-relations page. That report will place the revised revenue range against fresh volume and pricing data.
Price and company profile
Myriad Genetics develops molecular diagnostic tests in oncology, women's health and pharmacogenomics. Its Nasdaq-listed stock had a market capitalization of USD 545.7 million on October 20, 2026, while its 52-week range was USD 2.74 to USD 8.50.
The further course of trading is shown by the continuously updated real-time quote of Myriad Genetics stock.
Myriad Genetics stock at a glance
- Company: Myriad Genetics, Inc.
- ISIN: US62855J1043
- Ticker: MYGN
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 20, 2026, 8:35 p.m. CEST: EUR 5.07
- Market capitalization: USD 545.7 million (as of October 20, 2026)
- 52-week range: USD 2.74-8.50 (as of October 20, 2026)
- Sector / Industry: Healthcare / Medical Diagnostics and Research
Market context: Market report S&P 500.
